君实生物一季报:特瑞普利单抗国内收入同比增长45.72% 商业化能力夯实亏损持续收窄

中金在线
25 Apr

在特瑞普利单抗快速增长驱动下,君实生物首季业绩实现“开门红”。4月25日,君实生物(1877.HK,688180.SH)发布一季报显示,其2025年第一季度实现营收5.01亿元,同比增长31.46%,延续上年良好态势;随着资源优化、提质增效取得积极进展,利润端亏损持续收窄,经营现金流同比继续好转。第一季度,君实生物研发投入3.51亿元,同比增长26.89%。在研发投入同比增长的前提下,实现同比减亏...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10